Literature DB >> 9566672

Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin.

K Søndergaard1, K Stengaard-Pedersen, H Zachariae, L Heickendorff, M Deleuran, B Deleuran.   

Abstract

In order to investigate whether soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) were present in scleroderma skin, and to compare their levels to concentrations measured in plasma and clinical parameters, we examined suction blister fluid and plasma from 13 patients with systemic sclerosis and 11 healthy volunteers. Suction blisters and biopsies were from the transition zone between normal skin and scleroderma, and uninvolved abdominal skin. The levels of sICAM-1 and sIL-2R were significantly increased in both plasma and suction blister fluid from systemic sclerosis patients compared with healthy volunteers. ICAM-1 was localized to vessels and perivascular mononuclear infiltrates by immunohistochemical methods. IL-2R was expressed by CD3-positive cells. The elevated levels of sICAM-1 and sIL-2R in suction blister fluid point towards activation of endothelial cells and T cells in both the transition zone and uninvolved skin of systemic sclerosis patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566672     DOI: 10.1093/rheumatology/37.3.304

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  11 in total

1.  Dermatan sulfate activates nuclear factor-kappab and induces endothelial and circulating intercellular adhesion molecule-1.

Authors:  S F Penc; B Pomahac; E Eriksson; M Detmar; R L Gallo
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis.

Authors:  H U Scherer; G-R Burmester; G Riemekasten
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

Review 3.  The role of the acquired immune response in systemic sclerosis.

Authors:  Carlo Chizzolini; Francesco Boin
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

4.  T cell repertoire in patients with stable scleroderma.

Authors:  K P Tiev; J Abriol; M C Burland; D Antonelli; D Klatzmann; J Cabane; O Boyer
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 5.  Cytokine profiles in localized scleroderma and relationship to clinical features.

Authors:  Katherine Kurzinski; Kathryn S Torok
Journal:  Cytokine       Date:  2011-05-04       Impact factor: 3.861

6.  A study on soluble intercellular adhesion molecule-1 and selenium in patients with rheumatoid arthritis complicated by vasculitis.

Authors:  Anna Maria Witkowska; Anna Kuryliszyn-Moskal; Maria Halina Borawska; Katarzyna Hukałowicz; Renata Markiewicz
Journal:  Clin Rheumatol       Date:  2003-11-11       Impact factor: 2.980

Review 7.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

8.  Intracellular free radical production by peripheral blood T lymphocytes from patients with systemic sclerosis: role of NADPH oxidase and ERK1/2.

Authors:  Donatella Amico; Tatiana Spadoni; Marina Rovinelli; Marta Serafini; Giovanna D'Amico; Nadia Campelli; Silvia Svegliati Baroni; Armando Gabrielli
Journal:  Arthritis Res Ther       Date:  2015-03-17       Impact factor: 5.156

9.  Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis.

Authors:  Kristina En Clark; Henry Lopez; Bahja Ahmed Abdi; Sandra G Guerra; Xu Shiwen; Korsa Khan; Oseme Etomi; George R Martin; David J Abraham; Christopher P Denton; Richard J Stratton
Journal:  Arthritis Res Ther       Date:  2015-03-23       Impact factor: 5.156

Review 10.  On the role of sIL-2R measurements in rheumatoid arthritis and cancers.

Authors:  Anna Maria Witkowska
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.